The pregnant woman (the first in Greece) who received treatment with monoclonal antibodies against Covid-19 was at high risk of developing serious disease. So far a total of 40 patients have received treatment with intravenous infusion and the course of all so far is smooth.
The 2,000 new state-of-the-art treatments recently supplied by our country to treat patients with Covid-19 who are at increased risk of hospitalization are not being administered rapidly, despite initial fears that there would be increased demand.
It may, as doctors now say, exist over-tightening of treatment inclusion criteria. It should be noted that today the beneficiaries are those immunocompromised patients and vulnerable groups at very high risk, over 12 years of age with confirmed Covid-19 disease by last five days molecular PCR test.
Monoclonal Antibodies: Diabetics and Patients with Respiratory Impairment in New Beneficiaries
The competent scientific committee that drafted the protocols, in a meeting last night (06.12.2021) decided the expansion of the beneficiaries. Thus, monoclonal antibody therapies are expected to include, but are not limited to, obese, diabetic patients and those with respiratory failure.
In a relevant question of iatropedia.gr, the President of the Hellenic Pulmonary Society and member of the committee that compiles the treatment protocols, Professor of Pulmonology Stelios Loukidis, says: This may be due to the fact that we have only identified groups at very high risk for receiving the antibodies. It is not for the serious disease. It is for very fast administration for a disease that has the conditions to become serious.
It is also true that there is a skepticism in the world. Unjustified of course, because there are positive results from the studies. If the groups of beneficiaries open, we will do more treatments “.
Positive messages from the 40 patients who received the first treatments
So far, the response to treatment of the first 40 patients who received the monoclonal antibodies about 10 days ago is positive. Both the first patient injected with the drug at Sotiria Hospital and the next three show at present that respond positively to treatment.
However, all patients will remain in close medical follow-up for 28 consecutive days, until they are classified as “disease free”.
“Only 10 days have passed since the first patient. We record and we will see. It ‘s still early. We have to see by the 28th day what has happened. In all studies it is 28 days to get rid of the disease. We will have in a few days, detailed data which we are now recording together with the ministry “, concludes the professor of Pulmonology, Stelios Loukidis.
Monoclonal Antibodies: In 10 hospitals with the possibility of expansion
Right now, they exist 10 selected hospitals, in which there is the infrastructure and know-how for the administration of monoclonal antibodies. Are the following: Sotiria, Sismanogleio, AHEPA, Papageorgiou, Lamia and the Universities of Alexandroupolis, Larissa, Ioannina, Patras-Rio and Heraklion.
The process is done through an electronic platform. There, the treating doctors submit the request for the inclusion of their patients in the treatment. Priority of applications is based on the time of their submission to the electronic system and beneficiaries are patients who meet the criteria, as determined by the National Commission for the Protection of Public Health against Covid-19 infection.
To date, these have been patients belonging to vulnerable very high risk groups, over 12 years, with confirmed disease by PCR test, which has been performed during the last five days.
Once the application is submitted, the patient receives an SMS on his mobile phone to confirm or reject the request. In case of approval he goes to the hospital with a scheduled appointment. The treatment process takes half an hour. The patient then returns home and is placed under medical supervision for 28 days.
Reportage: Gianna Soulaki / Source: iatropedia.gr
The article Monoclonal antibody therapy in a pregnant woman and 40 other patients – What changes published in NewsIT .